RT Book, Section
A1 Gammal, Roseann S.
A1 Cavallari, Larisa H.
A1 Lam, Y. W. Francis
A2 DiPiro, Joseph T.
A2 Yee, Gary C.
A2 Michael Posey, L.
A2 Haines, Stuart T.
A2 Nolin, Thomas D.
A2 Ellingrod, Vicki L.
SR Print(0)
ID 1191225390
T1 Clinical Pharmacogenomics
T2 DiPiro: Pharmacotherapy A Pathophysiologic Approach, 12e
YR 2021
FD 2021
PB McGraw Hill
PP New York, NY
SN 9781260116564
LK accesspharmacy.mhmedical.com/content.aspx?aid=1191225390
RD 2022/06/25
AB KEY  CONCEPTS  Genetic  variation  contributes  to  pharmacokinetic  and  pharmacodynamic  properties  of  medications.  Genetic  variation  affects  drug-metabolizing  enzymes,  transporters,  and  target  proteins,  as  well  as  immune-related  proteins  that  may  impact  medication  response.  Genetic  polymorphisms  may  influence  medication  effectiveness  and  risk  for  toxicity.  Pharmacogenomics  is  the  study  of  the  impact  of  genetic  polymorphisms  on  medication  response.  The  goals  of  pharmacogenomics  are  to  optimize  medication  efficacy  and  limit  toxicity  based  on  an  individual’s  DNA.  Single  nucleotide  polymorphisms  are  the  most  common  gene  variations  associated  with  medication  response.  Evidence-based  resources,  such  as  US  Food  and  Drug  Administration  medication  labels,  Clinical  Pharmacogenetics  Implementation  Consortium  Guidelines,  and  the  Pharmacogenomics  Knowledgebase,  are  available  to  help  clinicians  select  and  dose  medications  based  on  a  patient’s  genetic  profile.  The  pharmacist  plays  a  key  role  in  advancing  pharmacogenomics  in  clinical  practice  as  part  of  a  multidisciplinary  healthcare  team.